To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

NCT06698484 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Relapsed/Refractory B- Cell Non-Hodgkin Lymphoma

Interventions

DRUG: CAR-T cells

Sponsor

National University of Malaysia

Collaborators

[object Object]